Ibrutinib, (S)- → Ibrutinib Racemate

HRID 1503467ノート

反応式

HRID 1503467 の反応式
[NH2:1][C:2]1[N:7]=[CH:6][N:5]=[C:4]2[N:8]([CH:24]3[CH2:29][CH2:28][CH2:27][N:26]([C:30](=[O:34])/[CH:31]=[CH:32]/C)[CH2:25]3)[N:9]=[C:10]([C:11]3[CH:16]=[CH:15][C:14]([O:17][C:18]4[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=4)=[CH:13][CH:12]=3)[C:3]=12.NC1N=CN=C2N(C3CCCN(S(C=C)(=O)=O)C3)N=C(C3C=CC(OC4C=CC=CC=4)=CC=3)C=12.NC1N=CN=C2N(C3CCCN(C(=O)C#C)C3)N=C(C3C=CC(OC4C=CC=CC=4)=CC=3)C=12.NC1N=CN=C2N(C3CCN(C(=O)C=C)CC3)N=C(C3C=CC(OC4C=CC=CC=4)=CC=3)C=12.NC1N=CN=C2N([C@@H]3CCN(C(=O)C=C)C3)N=C(C3C=CC(OC4C=CC=CC=4)=CC=3)C=12.NC1N=CN=C2N([C@H]3CCN(C(=O)C=C)C3)N=C(C3C=CC(OC4C=CC=CC=4)=CC=3)C=12.NC1N=CN=C2N([C@@H]3CCCN(C(=O)C=C)C3)N=C(C3C=CC(OC4C=CC=CC=4)=CC=3)C=12.NC1N=CN=C2N([C@H]3CCCN(C(=O)C=C)C3)N=C(C3C=CC(OC4C=CC=CC=4)=CC=3)C=12.NC1N=CN=C2N(C3CCCN(C(=O)/C=C/CN(C)C)C3)N=C(C3C=CC(OC4C=CC=CC=4)=CC=3)C=12>>[NH2:1][C:2]1[N:7]=[CH:6][N:5]=[C:4]2[N:8]([CH:24]3[CH2:29][CH2:28][CH2:27][N:26]([C:30](=[O:34])[CH:31]=[CH2:32])[CH2:25]3)[N:9]=[C:10]([C:11]3[CH:16]=[CH:15][C:14]([O:17][C:18]4[CH:19]=[CH:20][CH:21]=[CH:22][CH:23]=4)=[CH:13][CH:12]=3)[C:3]=12

参加物

10

反応物 9

HCID 24821023Ibrutinib, (S)-2 回HCID 24821094Ibrutinib2 回HCID 24821811HCID 24821811、化合物2 回HCID 24821812HCID 24821812、化合物2 回HCID 24821879HCID 24821879、化合物2 回HCID 248218802-Propen-1-one, 1-[4-[4-aMino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]-1-piperidinyl]-2 回HCID 24821882HCID 24821882、化合物2 回HCID 24821883HCID 24821883、化合物2 回HCID 24821941HCID 24821941、化合物2 回

生成物 1

HCID 16126651Ibrutinib Racemate

実験手順

(E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)but-2-en-1-one (Compound 5); 1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)sulfonylethene (Compound 6); 1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-yn-1-one (Compound 8); 1-(4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (Compound 9); N-((1s,4s)-4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)acrylamide (Compound 10); 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one (Compound 11); 1-((S)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one (Compound 12); 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (Compound 13); 1-((S)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (Compound 14); and (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-4-(dimethylamino)but-2-en-1-one (Compound 15).

出典と根拠

ORDレコード
ord-65e82ad7c17e451aafd197a983c70c8d
出典データセット
uspto-grants-2015_12
特許番号
US09212185B2

反応ノート

読み込み中…